Canaccord raised the firm’s price target on Thorne HealthTech to $6 from $5.50 and keeps a Buy rating on the shares. The analyst said as consumers increasingly take charge of their own health and wellness, we believe the company is well positioned to continue at its strong +20% top-line growth rate and expand its already healthy long-term EBITDA margins.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on THRN:
- Thorne HealthTech Reports Fourth Quarter and Full-Year 2022 Results
- Thorne HealthTech sees FY23 adjusted EPS 37c-39c, consensus 64c
- Thorne HealthTech reports Q4 adjusted EPS 13c vs. 7c last year
- Thorne HealthTech appoints Varma as new CFO
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue